麻豆视频

Europe Beta-Glucan Market Trends and Insights

Growing Consumer Interest in Immunity-Enhancing Functional Foods

Post-pandemic health priorities have pivoted toward proactive immune support, with 58% of European shoppers buying functional products primarily for immunity benefits. Beta-glucan brands are capitalizing by integrating clinically backed ingredients into snack bars, powders, and ready-to-drink beverages, especially in Northern Europe, where the willingness to pay premium prices is highest. EFSA-approved health claims grant marketing confidence, while specialized yeast and oat fractions enable clean-label positioning across multiple food matrices. Ingredient suppliers have intensified consumer-education campaigns in retail and e-commerce channels, translating academic research into approachable messaging that resonates with health-conscious audiences. The trend is expected to sustain revenue growth in the European beta-glucan market as household penetration widens in both mass and specialty retail formats.

Increasing Pharmaceutical Applications of Fungal and Yeast Beta-Glucans

Drug developers are leveraging beta-glucan鈥檚 immunomodulatory and controlled-release properties to improve bioavailability in oncology, antifungal, and vaccine-adjuvant therapies. The European Medicines Agency鈥檚^{[2]Source: European Medicines Agency, 鈥淧ublic Summary for Ibrexafungerp,鈥� ema.europa.eu}orphan-drug designation for ibrexafungerp illustrates regulatory support for glucan-based therapeutics. German and Swiss firms are spearheading the scale-up of pharmaceutical-grade production, commanding price premiums that outstrip food-grade equivalents. The segment's key characteristics include standardized dosing, high purity levels, and thorough clinical validation. These attributes ensure consistent product quality and reliable therapeutic outcomes. The rigorous scientific approach and proven efficacy attract substantial venture capital funding and public-sector grants focused on addressing antimicrobial resistance and chronic diseases. The successful commercialization of products increases ingredient demand across pharmaceutical and nutraceutical applications. This market growth strengthens the position of fungi- and yeast-derived molecules in the European beta-glucan market, particularly in therapeutic and preventive healthcare solutions.

Adoption in Dairy Alternatives and Plant-Based Beverages

Europe鈥檚 plant-based beverage boom positions beta-glucan as a multifunctional ingredient that delivers creamy mouthfeel, viscosity control, and heart-health benefits. Oat-drink manufacturers in the UK and Scandinavia are incorporating oatwell-branded beta-glucan to substantiate on-pack cholesterol-reduction claims, differentiating their SKUs in a crowded shelf set. Processing advances in enzymatic hydrolysis are producing highly soluble fractions suitable for low-viscosity beverages, thereby overcoming historical formulation hurdles. Regulatory certainty around on-pack claims provides marketing leverage, and consumer preference for plant-based nutrition supports premium pricing. This driver will continue to stimulate demand for specialty beta-glucan fractions and promote cross-category innovation in the European beta-glucan market.

Expanding Consumer Focus on Heart-Health Products

An aging European demographic pushes cardiovascular wellness to the forefront, prompting high interest in pantry staples that reduce LDL cholesterol. EFSA recommends 3 g daily beta-glucan intake for cholesterol management, giving formulators a clear target for efficacy. New research on high-solubility fibers shows improved glucose regulation, broadening health-positioning angles beyond traditional cholesterol reduction.Healthcare providers are incorporating functional foods into preventive care protocols, which maintains consistent demand through supermarket and pharmacy distribution channels. The integration of these products into preventive healthcare strategies reflects a broader shift toward proactive health management. Companies offering beta-glucan products with effective dosage formulations are positioned to benefit from the growing European market's focus on preventive healthcare spending. This alignment with preventive health trends creates opportunities for manufacturers to develop innovative formulations that meet both clinical requirements and consumer preferences.

Regulatory Hurdles and Ingredient-Approval Delays

While EFSA approvals provide a safety net, average 38-month review times burden innovators with high dossier-preparation costs, particularly for microalgae and bacterial sources. Post-Brexit divergence adds complexity, as the UK鈥檚 Nutrition and Health Claims Committee applies different evidence thresholds, creating fragmented market rules, according to the Government of UK^{[3]Source: GOV.UK, 鈥淯K Nutrition and Health Claims Committee 2024 Opinions,鈥� gov.uk}. Small biotechnology companies experience significant financial constraints and operational challenges during the lengthy regulatory approval process, giving larger competitors with substantial compliance budgets and established resources a distinct competitive advantage in the market. Companies that successfully receive regulatory approval gain valuable multi-year market exclusivity rights, as demonstrated by Kemin's five-year protection period for its Euglena-based BetaVia product. This exclusivity period enabled Kemin to establish early market leadership and maintain a strong position in the European beta-glucan segment, highlighting the importance of securing regulatory approvals in the biotechnology industry.

Inconsistent Performance Among Different Ingredient Sources

Weather variations and processing methods significantly affect beta-glucan content in cereal crops, creating substantial challenges for food manufacturers in maintaining consistent specifications. Thermal processes, particularly pressure cooking, decrease functional viscosity, which directly impacts the efficacy of health claims in final products. Suppliers lacking advanced analytical laboratories encounter significant difficulties in ensuring product consistency across batches, leading brand owners to increasingly select vertically integrated or thoroughly audited supply partners. These ongoing challenges drive substantial interest in controlled microalgae and fungal fermentation systems that provide enhanced parameter management and consistent output quality. Additionally, these market dynamics encourage extensive investment in rapid-testing technologies throughout the European beta-glucan market, enabling better quality control and regulatory compliance.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Source: Cereals and Grains Dominance Faces Biotechnology Challenge

Cereal and grains commanded 39.72% of the Europe beta-glucan market share in 2025 due to entrenched oat and barley supply chains and strong consumer familiarity with grain-based nutrition. Fungal beta-glucans, though smaller in scale, are on track for 8.62% CAGR growth as controlled indoor cultivation delivers predictable yields with elevated purity. The Europe beta-glucan market size for fungal sources is projected to expand materially as pharmacopoeia-grade demand gains traction in Germany and Switzerland. Yeast sources benefit from pharmaceutical validation and consistent fermentation outputs, reinforcing interest from pharma ingredient buyers. Meanwhile, microalgae have begun to commercialize following EFSA鈥檚 2024 nod, signaling further diversification and supply-chain resilience. Extraction innovation, like ultrasound-assisted autolysis, achieving 41.34% yield from winery yeast lees, exemplifies circular-economy potential that appeals to ESG-conscious manufacturers.

Competitive intensity within cereal supply is rising as the BARLEYboost consortium refines milling methods that could lift barley consumption by 100,000 t annually in the EU, thereby safeguarding beta-glucan supply amid climate variability. Concurrently, biotechnology startups are exploring Agrobacterium pusense and other bacterial candidates, anticipating novel-food status and opening new revenue streams. The interplay between tradition and innovation therefore defines the source landscape and will continue to shape procurement strategies in the Europe beta-glucan market.

By Category: Soluble Beta-Glucans Lead, While Insoluble Variants Show Strong Growth

Soluble fractions contributed 69.62% of 2025 revenue thanks to over three decades of cholesterol-lowering science and EFSA-approved heart-health claims. They maintain strong institutional acceptance, enabling formulators to hit 3 g daily dosage targets efficiently. Insoluble segment is projected to grow at 8.92% CAGR to 2031 on the back of novel texturizing roles and their incorporation into sustained-release nutraceutical tablets. High-shear dispersion and enzymatic tailoring are blurring traditional solubility lines, allowing developers to fine-tune viscosity without compromising digestibility.

Clinical studies on high-solubility variants demonstrate elevated glucose-regulation efficacy at lower viscosity, making them attractive for ready-to-drink beverages where mouthfeel remains critical. Meanwhile, insoluble derivatives are gaining traction in bakery, meat analogues, and wound-care dressings where water-binding is a key performance metric. These dual growth pathways ensure that both categories will coexist as distinct yet complementary offerings, thereby extending addressable sectors for the Europe beta-glucan market.

By Application: Food and Personal Care Lead Beta-Glucan Market Growth

Food and beverage applications maintained a dominant 45.96% revenue share in 2025, building on established cereal processing capabilities and consumer acceptance of oat-based health benefits. Personal care applications are projected to grow at 8.74% CAGR, driven by clinical evidence supporting beta-glucan's anti-wrinkle and wound-healing properties, aligning with European consumer preferences for dermocosmetic products. The ingredient has gained prominence in premium moisturizers and after-sun formulations, reflecting the broader industry shift toward natural active ingredients.

The pharmaceutical segment commands premium pricing through the incorporation of pharmaceutical-grade beta-glucan in therapeutic applications and drug-delivery systems. The animal feed segment maintains steady demand, as beta-glucan supplementation enhances gut immunity in poultry and swine production, supporting European initiatives to reduce antibiotic use. New applications, including biodegradable packaging, showcase beta-glucan's versatility and position it favorably under emerging sustainability regulations. These diverse applications demonstrate the expanding opportunities within the European beta-glucan market.

Geography Analysis

Rest of Europe held 38.21% of 2025 turnover due to a mosaic of small yet dynamic markets, from Switzerland鈥檚 pharma-focused demand to Poland鈥檚 rising functional-food manufacturers. The region鈥檚 fragmented regulatory regimes allow agile players to pilot new formats and niche positioning strategies without directly confronting the consolidated retail environments of France or Germany. Switzerland leads in pharmaceutical-grade formulations as high-margin hospital channels adopt beta-glucan adjunctive therapies. Austria and the Nordics drive organic and sustainable sourcing, increasing demand for traceable microalgae solutions.

Italy is set to advance at 7.94% CAGR through 2031 as cultural alignment with functional staples and public funding for Mediterranean-diet enhancement spur product innovation. The EU-backed Mush-Med project places Italian mills and bakeries at the forefront of mushroom-based glucan integration, creating regional clusters around Bologna and Parma. This collaborative ecosystem offers SMEs access to shared R&D infrastructure and rapid scale-up pathways, consolidating Italy鈥檚 strategic importance within the European beta-glucan market.

Germany, France, and Spain remain volume anchors. Germany鈥檚 pharma heavyweights insist on narrow quality specifications, encouraging suppliers to upgrade QC infrastructure. French dermocosmetic brands are infusing beta-glucan into anti-aging lines, reinforcing prestige positioning at pharmacies and beauty retailers. Spain leverages agronomic conditions ideal for high-beta-glucan barley and oat varieties, underscoring potential to become a raw-material hub. The UK contends with dual regulatory tracks after Brexit, yet homegrown brands are crafting UK-specific dosing statements to maintain consumer trust under evolving local guidelines. Collectively, these national dynamics ensure geographic diversification of revenue streams throughout the Europe beta-glucan market.

Regulatory Landscape

The European beta-glucan market operates under the EU novel food framework, anchored by Regulation (EU) 2015/2283 and the Union list approach (as set out in Regulation (EU) 2017/2470), with safety opinions delivered through EFSA assessments. A recent anchor event is the authorization of beta-glucan from Euglena gracilis microalgae (paramylon) via Commission Implementing Regulation (EU) 2024/1046 (9 April 2024). The measure formalized conditions of use for this non-traditional source and broadened the set of legally marketable beta-glucan origins beyond oats, barley, and established yeast processes.

Legacy authorizations continue to shape commercialization pathways for yeast-derived beta-glucans, including decisions that define conditions of use and maximum levels in specific end uses (for example, authorized uses in food supplements and certain food categories). For new entrants, compliance depends on whether the specific source and production process are already covered by an authorization, and whether the intended application fits the authorized conditions of use and target-population restrictions, which can vary by source even when the ingredient name is similar.

Value Chain Analysis

The Europe beta-glucan value chain begins with raw-material supply from (i) cereals, primarily oat and barley streams, often including milling by-products, and (ii) fermentation systems for yeast-derived beta-glucans, frequently linked to brewing and industrial fermentation side-streams. Ingredient production then moves through extraction, purification, and standardization steps (commonly aqueous extraction followed by precipitation, drying, and micronization) to reach application-specific purity and performance targets, with downstream distribution primarily through B2B ingredient channels into food and beverage, dietary supplements, personal care, and pharmaceuticals.

Industrial capacity and know-how cluster around cereal-processing ecosystems in Northern Europe and fermentation-processing hubs in Northern Germany, Benelux, and Scandinavia, with operators such as GoodMills Innovation GmbH active in cereal-based ingredient processing. Key bottlenecks and value-add points center on quality management (molecular weight, viscosity retention, and batch-to-batch consistency), analytical validation for claim-relevant functionality, and regulatory gatekeeping for novel sources, highlighted by the April 2024 authorization of Euglena gracilis beta-glucan under Commission Implementing Regulation (EU) 2024/1046.

Market Opportunities and Future Outlook

Commercial whitespace is emerging around non-traditional, more controllable supply models (fermentation and microalgae) that address the restraint of inconsistent cereal-linked performance and raw-material variability. The April 2024 EU authorization of Euglena gracilis microalgae-derived beta-glucan (Commission Implementing Regulation (EU) 2024/1046) gives formulators and suppliers a clear route to diversify sourcing while remaining inside the EU novel food framework. It also supports premium positioning where purity and standardization matter, particularly in supplements, personal care actives, and pharma-adjacent uses.

Beyond beta-glucan itself, moves across the broader fermented-ingredient ecosystem point to practical routes for scaling inputs that can feed beta-glucan-adjacent innovation. In April 2026, FERM FOOD acquired and began ramping up a former Orkla site in Skovlund, Denmark, targeting up to 20,000 tonnes per year of fermented ingredients. This illustrates active investment in fermentation infrastructure that can expand the pool of functional ingredient production in Europe. At the same time, specialist players stress differentiated production and form factors, including yeast side-stream upcycling models (for example, Yeastup) and preservation of bioactive configurations for mushroom-derived beta-1,3-glucans (for example, GlycaNova), which supports formulation-led segmentation across immune-supportive foods, supplements, and dermocosmetics.